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Abstract
Alzheimer’s Disease (AD) is the most prevalent form of dementia worldwide, yet the development of therapeutics has been
hampered by the absence of suitable biomarkers to diagnose the disease in its early stages prior to the formation of
amyloid plaques and the occurrence of irreversible neuronal damage. Since oligomeric Ab species have been implicated in
the pathophysiology of AD, we reasoned that they may correlate with the onset of disease. As such, we have developed a
novel misfolded protein assay for the detection of soluble oligomers composed of Ab x-40 and x-42 peptide (hereafter Ab40
and Ab42) from cerebrospinal fluid (CSF). Preliminary validation of this assay with 36 clinical samples demonstrated the
presence of aggregated Ab40 in the CSF of AD patients. Together with measurements of total Ab42, diagnostic sensitivity
and specificity greater than 95% and 90%, respectively, were achieved. Although larger sample populations will be needed
to confirm this diagnostic sensitivity, our studies demonstrate a sensitive method of detecting circulating Ab40 oligomers
from AD CSF and suggest that these oligomers could be a powerful new biomarker for the early detection of AD.
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Introduction
Alzheimer’s Disease (AD) is a neurodegenerative disorder
characterized by progressive memory loss and cognitive dysfunc-
tion. It is the most prevalent form of dementia, estimated to affect
13 million people worldwide [1]. While the precise mechanism
underlying the disease is not fully understood, the aggregation of
amyloid beta (Ab) appears to play an important role [2–4]. Ab
peptides of various lengths (typically 1–40 and 1–42) are cleavage
products of the amyloid precursor protein that aggregate and form
insoluble plaques in AD brains. Post mortem identification of these
plaques together with neurofibrillary tangles and neuronal loss is
currently the definitive and only fully accepted diagnostic
confirmation of AD [5,6]. However, recent reports suggest that
smaller, soluble Ab oligomers are more likely to be the pathogenic
agents of disease [3,4,7–10].
A growing number of in vitro generated oligomers of varied
size and structure have been implicated in AD [4]. However, the
actual identity of the oligomer participating in AD pathogenesis
remains elusive. Its chemical composition is also poorly defined,
although several lines of evidence suggest that AD-associated
oligomers are primarily composed of Ab42 [3]. For instance, one
unifying feature of AD is the presence of Ab42-containing
plaques in the brain parenchyma [11,12]. This suggests that any
soluble oligomers would also be composed of Ab42. In addition,
Ab42 appears to be more amyloidogenic than Ab40 and is found
more frequently in plaques despite existing at much lower
physiological concentrations [13]. Lastly, several presenilin
mutations linked to familial forms of AD are known to increase
production of Ab42 cleavage products [14], further implicating
this Ab peptide in pathogenesis. Consequently, it is generally
assumed that cytotoxic oligomers mediating AD are composed of
Ab42 peptides.
While the precise conformation of in vivo oligomers is
unknown, several lines of evidence suggest that aggregated
proteins share a number of structural properties. For instance,
amyloid fibrils composed of different proteins have similar cross
beta sheet structure, allowing binding and detection by a number
of compounds such as Thioflavin T and Congo Red [15,16].
Smaller aggregated species such as oligomers and protofibrils also
share structural properties recognized by conformation-sensitive
antibodies [17,18]. Similarly, we have recently developed a series
of peptides for the selective capture of aggregated prion protein
(PrP) from plasma [19]. We now report the adaptation and
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integration of these peptides into a Misfolded Protein Assay (MPA)
and the capture of aggregated Ab from CSF. Given that soluble
Ab oligomers have been reported in the CSF of AD patients
[10,20–22], we reasoned that the MPA could be utilized to detect
oligomers found in vivo. Using this technology, we demonstrate for
the first time the presence of Ab40 oligomers in AD CSF. We
propose that Ab40 oligomers could be a novel biomarker for the
early diagnosis of AD.
Methods
MPA capture of Ab aggregates
Aggregate Specific Reagent 1 (ASR1) beads were generated by
chemical conjugation of a thiolated ASR1 derivative to Dynal
M270 carboxyl beads (Invitrogen Dynal AS, Oslo, Norway,
30 mg/mL) via maleimide chemistry (Figure 1). Control beads
consisted of similarly conjugated glutathione molecules.
Ab42 aggregates from AD brain homogenate (ADBH) were
captured with 3 ml ASR1 beads for 1 hour at 37uC in 100 ml 80%
plasma by spiking with 75 nl of 10% brain homogenate (Fig. 2C)
or the indicated concentrations of Ab aggregates (Fig. 2D) in
capture buffer (50 mM Tris, 150 mM NaCl, 1% Tween-20, 1%
Triton X-100 pH 7.5). 10% ADBH was estimated to contain
,1 pg/nL Ab42 aggregates (data not shown). The beads were
then washed with TBST (50 mM Tris, 150 mM NaCl, 0.05%
Tween-20 pH 7.5), and bound proteins were eluted with 0.1 M
NaOH at 80uC for 30 minutes and neutralized with 0.12 M
NaH2PO4, 0.4% Tween-20. The eluted Ab was subsequently
detected by an Ab42-specific ELISA, utilizing an Ab x-42 specific
capture antibody (12F4, Covance, Princeton, NJ) and HRP-
conjugated 4G8 antibody (Covance) for detection. To test the
conformational nature of ASR1 binding, ADBH was pretreated
with 5.4 M guanidine thiocyanate for 30 minutes at room
temperature prior to dilution into 80% plasma and MPA
detection. AD and control brain samples were obtained from the
tissue bank of the Swiss National Reference Centre of Prion
Diseases (Zu¨rich, Switzerland).
In vitro Ab42 oligomers spiked into normal CSF and in vivo
oligomers from clinical AD CSF were similarly detected by the
MPA with a few modifications. 250 ml 80% human CSF in
capture buffer was incubated with 30 ml ASR1 beads. ASR1 beads
were subsequently washed with TBST and 1% Zwittergent 3-14
before Ab42 and Ab40 were eluted and detected in a multiplex
format by MSD immunoassay (Meso Scale Discovery, Gaithers-
burg, Maryland) according to the manufacturer’s instructions. In
vitro Ab42 oligomers are estimated to be 12mers and were
prepared as described [23]. Normal pooled CSF for oligomer
spiking experiments was purchased from Analytical Biological
Services Inc. (Wilmington, DE).
Biochemical characterization of brain-derived aggregates
Solubility of brain-derived Ab aggregates was assessed by
differential centrifugation. 250 nl 10% ADBH diluted into 0.5x
capture buffer was treated with or without 3 M guanidine
thiocyanate for 10 minutes at 95uC and then centrifuged for
1.5 hour at 134,000 g at 4uC. Ab42 in supernatant and pellet
fractions were denatured with 3 M guanidine, diluted with TBST
buffer, and detected by ELISA.
The size of brain-derived Ab42 aggregates was estimated by
separation of 75 ml of 10% ADBH on a Superdex200 10/300 GL
column at a flow rate of 1 mL/min in TBS with 1 mM EDTA,
1% NP40. 1 mL fractions were collected and denatured with 0.1
N NaOH as stated above prior to ELISA detection.
ELISA
ELISA plates were coated with 2 mg/mL 12F4 antibody in
coating buffer (0.1 M NaH2PO4, 1% NaCl, pH 6), washed with
TBST, and blocked with 1% BSA, 3% sucrose in TBS for 1 hour
at 37uC. 0.2 mg/mL HRP-conjugated 4G8 antibody in conjugate
diluent (0.1% BSA, 0.01% casein in PBS) was diluted 1:1 with the
sample and applied to the 12F4-coated plates for 1 hour at room
temperature before detection by a chemiluminescent substrate
(Pierce Supersignal ELISA Femto Substrate, Thermo Fisher
Scientific, Rockford, IL).
Patients and CSF sampling
The AD group consisted of 26 patients consulting the memory
disorder clinic at Malmo¨ University Hospital, Sweden, mean age
71.867.3 years. All patients underwent physical, neurological and
psychiatric examination, cognitive tests, careful clinical history and
functional assessment. Patients diagnosed with AD had to meet the
DSM-IIIR criteria of dementia [24] and the criteria of probable AD
defined by NINCDS-ADRDA [25]. The AD patients were followed
over time with repeated clinical evaluations, which increases the
clinical diagnostic accuracy. The control group, in total 10 cases,
mean age 69.469.7 years, was defined based on absence of memory
complaints or any other cognitive symptoms, and no signs of active
neurological or psychiatric disease. All patients and controls gave
informed consent to participate in the study. The study was
conducted according to the provisions of the Helsinki Declaration
and was approved by the ethics committee of Lund University,
Sweden. CSF was collected in polypropylene tubes, centrifuged,
aliquoted, and stored at 280uC pending analyses.
Statistical analysis
Statistical comparison of two populations was performed using
two-tailed t-test using GraphPad Prism for Windows, v 5.01
(GraphPad Software, San Diego, CA). Receiver operating
Figure 1. Aggregate Specific Reagent 1 (ASR1). Chemical structure of ASR1 peptoid conjugated to a solid surface.
doi:10.1371/journal.pone.0015725.g001
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characteristic curves (ROC) were generated using R (R Founda-
tion for Statistical Computing, Vienna, Austria).
Results
An aggregate-specific reagent captures Ab aggregates
from AD brain homogenate in a conformation-
dependent manner
We have developed an Aggregate Specific Reagent (ASR1,
Figure 1) that preferentially binds aggregated proteins over
monomeric proteins. ASR1 is a peptoid, a peptidomimetic
containing N-substituted glycines [26], which have been shown
to be resistant to proteolytic digestion from enzymes commonly
found in body fluids [27]. The ASR1 sequence is derived from a
PrP peptide that has a strong ability to capture aggregated PrP in
solution [19]. ASR1 can capture picomolar amounts of insoluble
aggregated PrP from a solution containing an excess of normally
folded PrP (Figure S1 and [19]).
As amyloid aggregates are characterized by similar cross-beta
sheet structure, they share conformational epitopes that are
recognized by amyloid-binding molecules such as Congo Red
and thioflavin T [15,16] as well as conformation-specific
antibodies [17,18]. We hypothesized that ASR1 might also
Figure 2. MPA detection of a conformational epitope in Ab aggregates from AD brain homogenates (ADBH). A. ADBH was centrifuged
at 134,000g for 1 hr, and denatured Ab42 in the supernatant (S) and pellet (P) fractions was detected by ELISA. B. ADBH was fractionated by size
exclusion chromatography and Ab42 was detected by ELISA. C. 75 nl of normal (open symbols) or AD (closed symbols) brain homogenate was
subjected to the MPA using control (triangles) or ASR1-coated (circles) beads. D. Ab aggregates from an ADBH were examined by the MPA with (open
symbols) or without (filled symbols) a pretreatment with 5.4 M guanidine thiocyanate using control (triangles) or ASR1-coated (circles) beads. Error
bars represent the standard deviation of triplicate reactions.
doi:10.1371/journal.pone.0015725.g002
Figure 3. MPA detection of synthetic oligomers at subpicomo-
lar levels. In vitro synthesized Ab42 oligomers were diluted into
normal CSF at the indicated concentrations and detected by the MPA.
Error bars represent the standard deviation of triplicate reactions.
doi:10.1371/journal.pone.0015725.g003
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recognize structural epitopes common to aggregated proteins
rather than epitopes specific to PrP aggregates. As such, we asked
if ASR1 could bind aggregates composed of Ab. Like brain-
derived PrP aggregates, aggregates from an AD brain homogenate
(ADBH) were insoluble at 134,000 g (Figure 2A), suggesting that
they were large. Fractionation by size exclusion chromatography
demonstrated that these aggregates were larger than a 670 kDa
molecular weight standard (Figure 2B).
To test if ASR1 could bind to Ab aggregates, ASR1 beads were
incubated with AD and normal brain homogenates, and then the
bound Ab42 was eluted, denatured, and then detected by an
Ab42-specific ELISA. This method, the MPA, could clearly
distinguish between control and AD samples, while a parallel assay
using a control bead could not (Figure 2C). Furthermore, ASR1
capture of Ab42 was conformation-dependent since treatment of
the aggregates with a chemical denaturant prior to the MPA
abolished all binding (Figure 2D).
ASR1 captures soluble oligomers in CSF
We reasoned that ASR1 would be a powerful tool for early
diagnosis of AD if, in addition to the large aggregates found in AD
brain tissue, it could also capture the smaller oligomers implicated
in AD pathogenesis. As such, we tested whether ASR1 could
capture Ab oligomers diluted into CSF. In vitro oligomers
composed of ,12 Ab42 monomers were prepared as described
[23] and diluted at varying concentrations into normal CSF before
being subjected to the MPA (Figure 3). Of note, the MPA could
detect the oligomers with high sensitivity with a limit of detection
of 5 pg/mL Ab42 (corresponding to ,80 fM oligomer).
ASR1 detects Ab40 oligomers in AD CSF
Because we achieved significant sensitivity at detecting in vitro
oligomers spiked into normal CSF, we asked whether the MPA
could detect endogenous oligomers reported to be present in AD
Figure 4. MPA detection of Ab40 oligomers from AD CSF. Normal (open circles) and AD (closed circles) CSF were analyzed by the MPA.
Oligomers containing Ab42 (A) and Ab40 (B) were captured by ASR1 beads followed by detection using a multiplex immunoassay. Significant
differences between normal and AD population were calculated by t-test (Ab42, p= 0.31; Ab40, **p,0.01). C. Lack of correlation between MPA-
detected Ab40 signal and the concentration of Ab40 monomers in AD CSF (R2 = 0.037). D. The distribution of Ab40 oligomers by disease severity was
examined by categorization of AD patients according to MMSE scores (**p,0.01 between normal and all AD groups). The mean and standard error of
the mean (SEM) are shown for all groups.
doi:10.1371/journal.pone.0015725.g004
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CSF [20–22]. CSF from 26 clinically diagnosed AD patients at
varying stages of disease and 10 aged-matched controls were
examined by the MPA. As before, CSF was incubated with ASR1
beads and the captured Ab was detected by a multiplex
immunoassay specific for Ab40 and Ab42. Upon examination of
captured Ab42, we did not detect any difference between AD and
control populations (Figure 4A). However, we observed surpris-
ingly clear and significant differences in the Ab40 signal between
the two groups (Figure 4B). Importantly, Ab40 signals from the
MPA did not correlate with the concentration of total Ab40 in the
CSF (presumably this immunoassay format would bias the
detection of total Ab toward monomeric species, so they are
indicated as such henceforth). This suggests that the Ab40 signals
were associated with specific MPA oligomeric capture and not
nonspecific binding of Ab40 monomers to the capture beads
(Figure 4C). When we further categorized the AD samples into
groups of increasing disease severity based on clinical Mini-Mental
State Examination (MMSE) scores, we found that the Ab40
oligomers were not only found in individuals with late-stage AD
and low MMSE scores but also in patients with early stage AD and
higher MMSE scores (Figure 4D). Therefore, using the MPA, we
have identified Ab40 oligomers as a potential biomarker that could
diagnose AD in the early stages of disease.
Ab40 oligomers are a novel biomarker for the diagnosis
of AD
To validate our results against other investigated biomarkers for
AD, we also measured the levels of monomeric Ab42 in this set of
samples. As expected, Ab42 was significantly decreased in the CSF
of AD patients relative to normal individuals (Figure 5A),
consistent with previously published results [28]. Since low levels
of monomeric Ab42 and high levels of oligomeric Ab40 are linked
to AD, we combined the two biomarkers to strengthen their
predictive value. The resulting ratio of oligomeric Ab40 to
monomeric Ab42 indeed enhanced the differentiation of control
and AD populations (Figure 5B). Additional ROC analysis
demonstrated diagnostic sensitivity and specificity of 95% and
90%, respectively (Figure 6, Table 1). Positive and negative
predictive value was estimated to be near 95% and 90%,
respectively, whereas oligomeric Ab40 and monomeric Ab42
biomarkers alone had negative predictive values that were equal to
or less than 75% (Table 1).
Discussion
AD is a growing epidemic that impacts nearly 50% of our
elderly population greater than 85 years old [29]. However, the
development of therapeutics to treat the disease has been
hampered by the absence of suitable biomarkers to diagnose the
disease. Currently, a clinical diagnosis of AD can only be
confirmed with the identification of Ab plaques in postmortem
brain tissue [5,6]. Premortem clinical diagnosis is also problematic
as it relies heavily on subjective reporting and observed cognitive
decline that can occur over a period of years. Since the first clinical
signs of cognitive dysfunction may appear after significant
neuronal loss has occurred, there is a compelling need for
biomarkers that can diagnose early AD.
Because Ab oligomers are suggested to play a key role in AD
pathogenesis [3,4,7–10] and because they have been detected in
Figure 5. Synergistic combination of Ab40 oligomer signal with monomeric Ab42 concentration. A. The concentration of monomeric
Ab42 was measured in normal (open circles) and AD (closed circles) CSF (***p,0.001). B. The ratio of Ab40 oligomers (RLU) and Ab42 concentration
(pg/mL) was calculated and plotted for both normal (open circles) and AD (closed circles) populations (***p,0.001). Three AD samples were not
included in this analysis because of insufficient sample to measure Ab42 concentrations. The mean and SEM are shown for all groups.
doi:10.1371/journal.pone.0015725.g005
Figure 6. Receiver operating characteristic (ROC) curve. ROC
analysis was performed to compare the diagnostic value of 3
biomarkers: oligomeric Ab40 (– –), monomeric Ab42 (- - -), and the
ratio Ab40oligomer/Ab42monomer (––).
doi:10.1371/journal.pone.0015725.g006
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diagnostically relevant body fluids [10,20–22], we reasoned that
Ab oligomers could be a powerful AD biomarker predicting
disease progression. However, the concentration of oligomers in
CSF remains poorly defined and only a few studies estimate that
they may exist at very low levels [21,22]. Furthermore, these
studies did not distinguish between Ab40 and Ab42-containing
oligomers since they utilized either antibodies recognizing
oligomeric structure or oligomer-specific ELISAs that employed
capture and detection antibodies recognizing the same amino-
terminal epitopes. In this study, we report the development of a
novel assay that specifically detected low concentrations of
aggregated Ab in a small population of AD CSF. Because AD is
largely correlated with the accumulation of Ab42 in the brain, we
expected to identify oligomers composed of Ab42. To our surprise,
we found only an enrichment of Ab40-containing oligomers in AD
CSF. These oligomers were observed at multiple stages of AD,
suggesting that they could be a biomarker for early diagnosis of
AD.
Because Ab42 oligomers are widely implicated in AD
pathology, the correlation we observed of AD with Ab40 but
not Ab42 oligomers was surprising. One explanation is that we
detected oligomers associated with the vascular Ab40 deposits that
are seen in patients with cerebral amyloid angiopathy (CAA). CAA
is a pathological feature of AD characterized by the cerebrovas-
cular deposition of Ab peptides with the major species being Ab40
[30,31] and has been estimated to impact greater than 90% of AD
cases [32,33]. Therefore, our findings might reflect an increase of
oligomeric Ab40 associated with these Ab deposits.
Another possibility is that Ab40 oligomers may be more soluble
and reach CSF more readily than Ab42 oligomers which may
rapidly aggregate and deposit in the brain parenchyma.
Consequently, high levels of Ab40 oligomers in the CSF may be
a surrogate marker of an amyloidogenic cascade in the brain.
A third explanation for our inability to identify Ab42 oligomers
may be the sensitivity of our detection system. While both Ab40
and Ab42 containing oligomers may be present in CSF and
captured by ASR1 beads, the subsequent detection of the
constituent monomers may be limited by the sensitivity of the
immunoassay (Mesoscale detection limits for Ab40 and Ab42 are 5
and 8 pg/mL, respectively). Furthermore, the concentration of
Ab42 in CSF is approximately 10-fold lower than that of Ab40,
suggesting that any Ab42-containing oligomers may exist at
concentrations below our detection limit.
Although Ab40 aggregates have been documented in AD, the
biological relevance of Ab40 oligomers in AD pathogenesis
remains unclear. While nearly all cases of AD report Ab42-
containing plaques in the brain, approximately two thirds of them
also report Ab40 deposits [11], and significant levels of Ab40 have
also been found in AD cortical brain tissue [34]. One
interpretation of these results is that aggregation of the less soluble
Ab42 would precede and recruit subsequent aggregation of Ab40,
as has been previously suggested [12,35]. In support of this idea,
purification of oligomers from AD brain tissues have isolated both
Ab40, Ab42, and Ab40/42 heterodimers [8,36]. The impact of
Ab40 oligomers on AD pathogenesis is unclear although some in
vitro models suggest that Ab42 oligomers are significantly more
cytotoxic [37]. Nevertheless, preparations of soluble Ab40 are
sufficiently toxic to impact long term potentiation in cell culture
systems and cognitive function when injected into mice [38].
Additional studies are clearly needed to understand the role of
Ab40 oligomers in AD pathogenesis. Since oligomeric Ab is
suggested to be a direct causative agent of AD, we believe they
may be an ideal predictor of disease progression. Indeed, although
the results do not reach significance, our data suggest that there
could be an inverse correlation between oligomer concentration
and disease severity (Figure 4D) similar to the decline that is
observed in the Ab42 levels of AD patients. Future studies will
include larger patient populations and prospective CSF sampling
to screen for incipient AD. Additionally, if Ab oligomers are to
become a relevant biomarker for AD, its predictive value must be
measured in patients with mild cognitive impairment. Neverthe-
less, our results showing the detection of Ab40 oligomers in CSF
from patients in the initial stages of AD suggest that the MPA
could be a sensitive assay for the early diagnosis of AD.
Supporting Information
Figure S1 Prion Protein (PrP) captured from plasma
spiked with vCJD or normal brain homogenates. vCJD
(closed circle) and normal (open circle) brain homogenates were
spiked into normal human plasma at the indicated concentrations
and subjected to the MPA. Captured prion protein was eluted and
detected by a prion-specific ELISA. Materials and Methods: vCJD
and normal 10% brain homogenates (w/v) (‘‘Blue’’ and ‘‘Clear’’
samples, respectively, from National Institute for Biological
Standards and Control, United Kingdom) were spiked into
normal human plasma (SeraCare Life Sciences, West Bridgewater,
MA), after which 200 ml of the solution was incubated with 50 ml
of 5x capture buffer and 9 ml ASR1 beads for 1 hour at 37uC. The
beads were washed and captured prion protein was subsequently
eluted, denatured, and detected by sandwich ELISA [19]. The
vCJD brain homogenate had an estimated 4 mg/mL of aggregated
PrP.
(TIF)
Table 1. ROC analysis and diagnostic performance for Ab40 oligomer, Ab42 monomer, and Ab40oligomer/Ab42monomer biomarkers.
Parameters Ab40 oligomer Ab42 monomer Ab40oligomer/Ab42monomer
ROC AUC 0.93 0.93 0.98
Threshold value 850 RLU 150 pg/ml 4.3
Sensitivity (%) 81 87 96
Specificity (%) 90 90 90
Test accuracy (%) 83 88 94
Positive predictive value (%) 95 95 96
Negative predictive value (%) 64 75 90
doi:10.1371/journal.pone.0015725.t001
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